CJC-1295 (no DAC) + Ipamorelin
A combination of CJC-1295 and Ipamorelin designed to provide synergistic growth hormone release through complementary mechanisms.
What This Compound Is
This combination pairs CJC-1295 without DAC (a GHRH analogue) with Ipamorelin (a growth hormone secretagogue). The two peptides work through different mechanisms to stimulate growth hormone release. Researchers study this combination for its synergistic effects on GH secretion and metabolic processes in laboratory settings.
Research Interest
Scientific research on this combination examines the synergistic effects of GHRH and ghrelin receptor activation. Studies focus on how combined stimulation affects GH pulse amplitude, secretion frequency, and overall GH output. Researchers investigate the complementary mechanisms, reduced side effects compared to single agents, and enhanced metabolic outcomes in experimental models.
Educational Disclaimer
For laboratory research purposes only. Not for human consumption or clinical use. This product is intended solely for in-vitro research and educational applications.
Available Formats
Related Research Compounds
Explore similar peptides and compounds that researchers often study together